Risperidon

Risperidon: 4-30 microgram/L

9-hydroxyrisperidon: 12-60 microgram/L

Som risperidon + 9-hydroxyrisperidon: 20-60 microgram/L

Toxisch: som risperidon en 9OH-risperidon > 120 microgram/L

Verhoogde 9-hydroxyrisperidon spiegels zorgen voor verhoogde prolactine spiegels met daarbij seksuele disfunctie.

Bij de interpretatie van de resultaten dient rekening gehouden te worden met de meetonzekerheid van de analysemethode. Voor meer informatie kunt u terecht bij de laboratoriumapotheker.

ISO15189 M272 KF.TDM.02

-Hiemke et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. pharmacospychiatry 44:195-235 -Darby J K , Pasta D J , Wilson M G et al. Long-term therapeutic drug monitoring of risperidone and olanzapine identifi es altered steadystate pharmacokinetics: a clinical, two-group, naturalistic study . Clin Drug Investig 2008 ; 28 : 553 – 564 -Locatelli I , Kstelic M . Kores-Plesnicar et al. A population pharmacokinetic evalutation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode schizophrenia . Eur J Pharm Sci 2010 ; 41 : 289 – 298 -Mauri M C , Laini V , Boscati L et al. Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels . Eur Psychiatry 2001 ; 16 : 57 – 63 -Medori R , Mannaert E , Gründer G . Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone longacting injectable . Eur Neuropsychopharmacol 2006 ; 16 : 233 – 240 -Nesvag R , Hendset M , Refsum H et al. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication . Acta Psychiatr Scand 2006 ; 114 : 21 – 26 -Nishikage H , Nakanishi T , Takamitsu Y et al. Sequential changes in the plasma concentration of risperidone following intentional overdose . Clin Neuropharmacol 2002 ; 25 : 307 – 309 -Remington G , Mamo D , Labelle A et al. A PET study evaluating dopamine D 2 receptor occupancy for long-acting injectable risperidone . Am J Psychiatry 2006 ; 163 : 396 – 401 -Riedel M , Schwarz M J , Strassnig M et al. Risperidone plasma levels, clinical response and side-eff ects . Eur Arch Psychiatry Clin Neurosi 2005 ; 255 : 261 – 268 -Spina E , Avenoso A , Facciolà G et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia . Psychopharmacology (Berl) 2001 ; 153 : 238 – 243 -Wong S L , Menacherry S , Mulford D et al. Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function . Eur J Clin Pharmacol 1997 ; 52 : 223 – 227 -Yin O Q , Wing Y K , Cheung Y et al. Phenotype-genotype relationship and clinical eff ects of citalopram in Chinese patients . J Clin Psychopharmacol 2006 ; 26 : 367 – 372 TDM monografie risperidon en paliperidon (www.tdm-monografie.org)